{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:09:09Z","timestamp":1790345349347,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00262-022-03320-3","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:08:42Z","timestamp":1668593322000},"page":"1225-1232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade"],"prefix":"10.1007","volume":"72","author":[{"given":"Aditya","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"3320_CR1","volume-title":"Immune checkpoint inhibitors in cancer","author":"F Ito","year":"2019","unstructured":"Ito F, Ernstoff MS (2019) Immune checkpoint inhibitors in cancer. Elsevier, Amsterdam"},{"key":"3320_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/OP.21.00305","volume":"17","author":"CE Steuer","year":"2021","unstructured":"Steuer CE, Ramalingam SS (2021) Advances in immunotherapy and implications for current practice in non-small-cell lung cancer. JCO Oncol Pract 17:662\u2013668","journal-title":"JCO Oncol Pract"},{"key":"3320_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA et al (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707\u2013723","journal-title":"Cell."},{"key":"3320_CR4","doi-asserted-by":"crossref","unstructured":"Lei Y, Li X, Huang Q, et al (2021) Progress and challenges of predictive biomarkers for immune checkpoint blockade. Frontiers in Oncology. Frontiers Media S.A","DOI":"10.3389\/fonc.2021.617335"},{"key":"3320_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang Z, Aguilar EG, Luna JI et al (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine 25:141\u2013151","journal-title":"Nature Medicine"},{"key":"3320_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1470-2045(19)30797-1","volume":"21","author":"A Sanchez","year":"2020","unstructured":"Sanchez A, Furberg H, Kuo F et al (2020) Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol 21:283\u2013293","journal-title":"Lancet Oncol"},{"key":"3320_CR7","doi-asserted-by":"crossref","unstructured":"Wang F, Zhou L, Chen N, et al (2021) The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy. Medicine, 100","DOI":"10.1097\/MD.0000000000024664"},{"key":"3320_CR8","doi-asserted-by":"publisher","first-page":"LMT26","DOI":"10.2217\/lmt-2019-0016","volume":"9","author":"A Gelibter","year":"2020","unstructured":"Gelibter A, Occhipinti M, Pisegna S et al (2020) Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung Cancer Manag 9:LMT26","journal-title":"Lung Cancer Manag"},{"key":"3320_CR9","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.3389\/fimmu.2021.668494","volume":"12","author":"KI Farag","year":"2021","unstructured":"Farag KI, Makkouk A, Norian LA (2021) Re-evaluating the effects of obesity on cancer immunotherapy outcomes in renal cancer: what do we really know? Front Immunol 12:3159","journal-title":"Front Immunol"},{"key":"3320_CR10","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/ijms22052628","volume":"22","author":"A Indini","year":"2021","unstructured":"Indini A, Rijavec E, Ghidini M et al (2021) Impact of BMI on survival outcomes of immunotherapy in solid tumors: a systematic review. Int J Molecular Sci 22:2628","journal-title":"Int J Molecular Sci"},{"key":"3320_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25:127\u2013141","journal-title":"Stat Med"},{"key":"3320_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European J Cancer 45:228","journal-title":"European J Cancer"},{"key":"3320_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"FE Harrell","year":"2015","unstructured":"Harrell FE (2015) Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis, 2nd edn. Springer International Publishing, Berlin","edition":"2"},{"key":"3320_CR14","unstructured":"R Core Team (2021) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. https:\/\/www.R-project.org."},{"key":"3320_CR15","doi-asserted-by":"crossref","unstructured":"Harrell FE (2021) RMS: regression modeling strategies. R package version 6.2\u20130. https:\/\/CRAN.R-project.org\/package=rms.","DOI":"10.32614\/CRAN.package.rmsb"},{"key":"3320_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","volume":"6","author":"G Kichenadasse","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA et al (2020) Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 6:512\u2013518","journal-title":"JAMA Oncol"},{"key":"3320_CR17","doi-asserted-by":"publisher","first-page":"e001403","DOI":"10.1136\/jitc-2020-001403","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Ricciuti B, Tiseo M et al (2020) Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: A multicenter study with external validation. J Immunother Cancer. 8:e001403","journal-title":"J Immunother Cancer."},{"key":"3320_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.lungcan.2020.04.034","volume":"145","author":"K Takada","year":"2020","unstructured":"Takada K, Takamori S, Yoneshima Y et al (2020) Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer 145:18\u201326","journal-title":"Lung Cancer"},{"key":"3320_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cncr.32576","volume":"126","author":"DJ Martini","year":"2020","unstructured":"Martini DJ, Kline MR, Liu Y et al (2020) Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 126:575\u2013582","journal-title":"Cancer."},{"key":"3320_CR20","doi-asserted-by":"publisher","first-page":"105745","DOI":"10.1016\/j.intimp.2019.105745","volume":"74","author":"H Xu","year":"2019","unstructured":"Xu H, Cao D, He A et al (2019) The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients. Int Immunopharmacol 74:105745","journal-title":"Int Immunopharmacol"},{"key":"3320_CR21","doi-asserted-by":"crossref","unstructured":"Naik GS, Waikar SS, Johnson AEW, et al (2019) Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer, 7","DOI":"10.1186\/s40425-019-0512-5"},{"key":"3320_CR22","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1200\/OP.20.01055","volume":"18","author":"M Krishnan","year":"2022","unstructured":"Krishnan M, Kasinath P, High R et al (2022) Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors. JCO Oncol Pract 18:e175\u2013e182","journal-title":"JCO Oncol Pract"},{"key":"3320_CR23","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","volume":"78","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Cespedes Feliciano EM, Kroenke CH (2018) the importance of body composition in explaining the overweight paradox in cancer\u2014counterpoint. Cancer Res 78:1906\u20131912","journal-title":"Cancer Res"},{"key":"3320_CR24","doi-asserted-by":"publisher","first-page":"e001674","DOI":"10.1136\/jitc-2020-001674","volume":"8","author":"P Johannet","year":"2020","unstructured":"Johannet P, Sawyers A, Qian Y et al (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 8:e001674","journal-title":"J Immunother Cancer."},{"key":"3320_CR25","doi-asserted-by":"crossref","unstructured":"Bai R, Lv Z, Xu D, et al (2020) Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research. BioMed Central","DOI":"10.1186\/s40364-020-00209-0"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03320-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03320-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03320-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T09:04:46Z","timestamp":1728378286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03320-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3320"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03320-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Patel serves on advisory board for Sanofi. Dr. Fujioka serves on advisory boards for Takeda Pharmaceutical and AstraZeneca. Dr. Kulkarni serves on advisory board of Genentech and has institutional grant funding from Astra Zeneca. Other authors declare they have no relevant financial or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This was a retrospective study done in compliance with the statute laid down by the University of Minnesota Institutional Review Board (STUDY00018385). No ethics approval or informed consent from individual participants was deemed required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}]}}